Want to see IN:JUBLPHARMA full AI Analyst Report?
JUBLPHARMA Stock Chart & Stats
₹962.00
₹14.35(1.49%)
At close: 4:00 PM EDT
₹962.00
₹14.35(1.49%)
Day’s Range― - ―
52-Week Range₹783.75 - ₹1,183.90
Previous CloseN/A
Volume117.87K
Average Volume (3M)7.42K
Market Cap
₹143.80B
Enterprise Value₹153.02K
Total Cash (Recent Filing)₹12.67B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)40.6
Beta1.06
Next Earnings
Oct 30, 2026EPS Estimate
5.8Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)22.24
Shares Outstanding159,281,140
10 Day Avg. Volume4,911
30 Day Avg. Volume7,424
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)1.82
Price to Sales (P/S)1.56
P/FCF Ratio-29.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.98
Revenue Forecast (FY)₹93.55B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line expansion indicates sustained demand across Jubilant Pharmova's pharmaceutical, CDMO, and life-sciences activities. Growth across multiple business lines can support scale, improve customer reach, and provide a durable base for future earnings recovery.
Diversified Life-Sciences ModelThe company participates across contract manufacturing, research services, APIs, and marketed medicines. This breadth diversifies revenue sources and gives it exposure to multiple stages of the pharmaceutical lifecycle rather than relying on one product or service category.
Positive Operating Cash FlowRegularly positive operating cash flow shows that core operations generate cash despite inconsistent free cash flow. This provides an underlying funding base for working capital, research, manufacturing operations, and other investments needed to sustain the business.
Bears Say
Volatile ProfitabilityLarge swings in profitability reduce earnings predictability and make sustained returns harder to assess. The FY2026 margin recovery weakened after FY2025, while the sharp gross-margin decline suggests exposure to product mix, pricing, or input-cost pressures.
Unreliable Free Cash FlowRepeated negative free cash flow indicates that earnings are not consistently converting into surplus cash. Reinvestment needs or working-capital swings may constrain debt reduction, shareholder returns, and the company's flexibility to fund growth internally.
Rising LeverageLeverage remains moderate but is moving higher as total debt increased in FY2026. Combined with volatile margins and weak free cash flow, rising borrowing could reduce financial flexibility and increase pressure on future cash generation.
Jubilant Pharmova Limited News
JUBLPHARMA FAQ
What was Jubilant Pharmova Limited’s price range in the past 12 months?
Jubilant Pharmova Limited lowest stock price was ₹783.75 and its highest was ₹1183.90 in the past 12 months.
What is Jubilant Pharmova Limited’s market cap?
Jubilant Pharmova Limited’s market cap is ₹143.80B.
When is Jubilant Pharmova Limited’s upcoming earnings report date?
Jubilant Pharmova Limited’s upcoming earnings report date is Oct 30, 2026 which is in 65 days.
How were Jubilant Pharmova Limited’s earnings last quarter?
Jubilant Pharmova Limited released its earnings results on Aug 10, 2026. The company reported ₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹5.8 by -₹2.3.
Is Jubilant Pharmova Limited overvalued?
According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Overvalued.
Does Jubilant Pharmova Limited pay dividends?
Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.56%. See more information on Jubilant Pharmova Limited dividends here
What is Jubilant Pharmova Limited’s EPS estimate?
Jubilant Pharmova Limited’s EPS estimate is 5.8.
How many shares outstanding does Jubilant Pharmova Limited have?
Jubilant Pharmova Limited has 159,281,140 shares outstanding.
What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?
Jubilant Pharmova Limited reported an EPS of ₹3.5 in its last earnings report, missing expectations of ₹5.8. Following the earnings report the stock price went up 3.214%.
Which hedge fund is a major shareholder of Jubilant Pharmova Limited?
Currently, no hedge funds are holding shares in IN:JUBLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jubilant Pharmova Limited
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment is involved in a range of activities, including the production and distribution of allergy treatments, outsourced manufacturing of both sterile injectable and non-sterile medications, the creation of active pharmaceutical ingredients (APIs), and solid dose formulations. This division also markets radiopharmaceuticals through a network of 48 specialized pharmacies located across the United States. Its Contract Research & Development Services arm offers collaborative scientific investigation to pioneering pharmaceutical companies. Furthermore, the Proprietary Novel Drugs segment focuses on developing innovative therapies for conditions such as cancer and autoimmune diseases. Established in 1978 and headquartered in Noida, India, the company was formerly named Jubilant Life Sciences Limited before adopting its current designation, Jubilant Pharmova Limited, in February 2021.
Technical Analysis
Glenmark Life Sciences Limited
―
Granules India Limited
―
Neuland Laboratories Ltd.
―
Strides Pharma Science Ltd
―
Wockhardt Limited
―